When was Mammoth founded?

Mammoth was founded in 2017 and became a unicorn in 2021.

Where is Mammoth located?

Mammoth is headquartered in Brisbane, United States.

Who is the current CEO of Mammoth?

Trevor Martin of Mammoth. They have also founded 1 company and are angel investors in 4 startups, including .

How many employees does Mammoth have?

As of Aug 31, 2026, the latest employee count at Mammoth is 160.

Is Mammoth a funded company?

Mammoth is a funded company, having raised a total of $271M across 7 funding rounds to date. The company's 1st funding round was a $120K Seed round, raised on Sep 14, 2017.

How much is Mammoth worth?

The latest valuation of Mammoth is $1B as of Dec 31, 2021.

When was the latest funding round of Mammoth?

Mammoth's latest funding was a $150M Series D round on Sep 09, 2021, with participation from 9 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.33B in funding in 2026 to date.

Is Mammoth a Genomics company?

The primary sectors of Mammoth are Genomics, Gastroenterology, Rare Diseases and Neurology.

Where does Mammoth rank among its competitors?

Mammoth ranks 22nd amongst 870 active competitors, of which 282 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was MapLight, which secured $150M in Aug, 2026.

Who are the top competitors of Mammoth?

Mammoth's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, MapLight secured the most recent funding round in August, 2026.

Mammoth - 2026 Company Profile, Team, Funding & Competitors

Mammoth is a series D company based in Brisbane (United States), founded in 2017 by Trevor Martin, Lucas Harrington and Jennifer Doudna. It operates as a Provider of molecular diagnostics platform by using CRISPR technology. Mammoth has raised $271M in funding from investors like Redmile Group, Mayfield and Decheng Capital, with a current valuation of $1B. The company has 870 active competitors, including 282 funded and 190 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Sectors and market segments that Mammoth operate in

Mammoth serves in the Life Sciences market segments.The primary business model of Mammoth are:

Company Details

Mammoth Biosciences offers a CRISPR data platform for diagnostics using Cas12 and Cas13 proteins. The company is creating a new class of diagnostics for industries ranging from oil and gas to agriculture to healthcare. The platform is used to identify disease-causing biomarkers (DNA/RNA).

Website: mammoth.bio
Social
Email ID: *****@mammothbiosci.com
Phone Number: +1 **********

Key Metrics

Founded Year

2017

Location

Brisbane, United States

Stage

Series D

Total Funding

$271M in 7 rounds

Latest Funding Round

Series D, Sep 09, 2021, $150M

Post Money Valuation

$1B as on Dec 31, 2021

Investors

Redmile Group & 35 more

Ranked

22^nd among 870 active competitors

Employee Count

160 as on Aug 31, 2026

Similar Companies

Beam Therapeutics & 341 more

View Mammoth's full profile

Mammoth has raised a total funding of $271M over 7 rounds. Its first funding round was on Sep 14, 2017. Its latest funding round was a Series D round on Sep 09, 2021 for $150M. 9 investors participated in its latest round. Mammoth has 32 institutional investors and 4 angel investors.

Here is the list of recent funding rounds of Mammoth:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 09, 2021	$150M	Series D	$1B	-	Redmile Group	Foresite Capital, Greenspring Associates, Decheng Capital, Mayfield, Senator Investment Group, Plum Alley Investments, NFX, Sixth Street
Jan 26, 2021	Undisclosed	Series C	-	-	-	-
2020	$45M	Series C	-	-	Redmile Group	Foresite Capital, Sixth Street, Decheng Capital, Mayfield, Amazon

Access funding benchmarks and valuations. Sign up today!

View details of Mammoth's funding rounds and investors

The founders of Mammoth are Trevor Martin, Lucas Harrington and Jennifer Doudna. Trevor Martin is the CEO of Mammoth.

Here are the details of Mammoth's key team members:

Trevor Martin: Co-Founder & CEO of Mammoth. They are also an angel investor in 4 startups.
Contact Info: 1 email address
Lucas Harrington: Co-Founder & CSO of Mammoth and founder of 1 other company.
Contact Info: 2 email addresses
Jennifer Doudna: Co-Founder of Mammoth.

View details of Mammoth's Founder profiles and Board Members

Mammoth's employee count trend

Mammoth has 160 employees as of Aug 26. Here is Mammoth's employee count trend over the years:

Uncover Mammoth's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Mammoth include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Mammoth, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	Redmile Group, Cormorant-asset & 16 others	71/100
5th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
6th	Pacira 2006, Parsippany Troy Hills (United States), Public	Developer of injectable non-opioid products for post-surgical pain control	$85M	Orbimed, HBM Healthcare Investments & 7 others	69/100
7th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
8th	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Vida Ventures, TPG & 4 others	68/100
9th	MapLight 2018, Redwood City (United States), Public	Developer of therapeutic for central nervous system disorders	$698M	Goldman Sachs, Cowen & 10 others	68/100
10th	Neurocrine 1992, San Diego (United States), Acquired	Developer of small molecule therapeutics for endocrine and CNS disorders	$10M	Venrock, BB Biotech & 6 others	68/100
22nd	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Foresite Capital, AME Cloud Ventures & 34 others	65/100